Nexodal (Naloxone Hydrochloride)

Naloxone, the active ingredient in Nexodal, is an opioid antagonist presented as an injectable solution for intramuscular and intravenous use. It rapidly reverses life‑threatening respiratory depression caused by opioid overdose in adults and children and is commonly stocked in emergency medical settings.

GNH USA supplies Nexodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation, ensuring reliable access for healthcare providers across the European Union and other markets.

Naloxone is an opioid antagonist used to counteract the effects of opioid toxicity.

Opioid overdose: rapidly restores normal breathing and consciousness in patients with life‑threatening respiratory depression. Opioid toxicity: reverses central nervous system depression caused by excessive opioid exposure. Post‑operative opioid reversal: counteracts residual opioid effects after surgery when rapid awakening is required.

Naloxone may be associated with several adverse reactions, most of which are related to its pharmacologic action or the injection process.

Common Side Effects: - Injection site pain: mild discomfort or bruising at the injection site. - Nausea: transient feeling of sickness that may resolve without treatment. - Sweating: increased perspiration often accompanying opioid withdrawal.

Serious or Rare Side Effects: - Severe hypertension: marked rise in blood pressure that may need medical attention. - Cardiac arrhythmias: irregular heart rhythms that can be life‑threatening. - Anaphylaxis: acute allergic reaction with hives, airway swelling, or shock.

When using Naloxone, healthcare professionals should follow specific safety measures to ensure effective reversal while minimizing risks.

- Assess airway and breathing: confirm respiratory depression before administration. - Confirm opioid involvement: ensure overdose is suspected or confirmed prior to use. - Monitor vital signs: observe blood pressure, heart rate and oxygen saturation after dosing. - Adjust for cardiovascular disease: use caution in patients with pre‑existing hypertension or heart conditions. - Watch for precipitated withdrawal: be prepared to manage acute withdrawal symptoms in opioid‑dependent individuals. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Naloxone can interact with other medicines, influencing its efficacy or increasing the risk of adverse events.

Major Interactions (Avoid): - Buprenorphine: may precipitate severe opioid withdrawal when naloxone displaces this partial agonist. - High‑dose opioid therapy: may reduce the effectiveness of naloxone, requiring repeated dosing. - Cardiovascular stimulants: concurrent use can exacerbate hypertension caused by naloxone.

Moderate Interactions (Monitor Closely): - Benzodiazepines: risk of recurrent respiratory depression after naloxone wears off. - Antihypertensive agents: may blunt the blood pressure rise associated with naloxone. - Tricyclic antidepressants: potential for increased cardiac arrhythmia risk during reversal.